Persistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2; [Персистенция новой коронавирусной инфекции у пациентки с первичной крупноклеточной В-клеточной лимфомой центральной нервной системы с оценкой гуморального иммунного ответа против SARS-CoV-2]

Treatment of immunocompromised patients with novel coronavirus infection (COVID-19) presents significant challenges. Currently, there are no unified approaches to the treatment of persistent COVID-19 in hematological malignancies. there is a need to develop recommendations for the management of such patients, chemotherapy protocols, as well as therapy for COVID-19 in case of SARS-CoV-2 virus persistence. Doctors are faced with cases of virus persistence, clinical manifestations during a long course of the infectious process and are not provided with methodological recommendations for patient supervision. As scientific data on the persistent COVID-19 course in patients with lymphoproliferative diseases accumulates, it is planned to create recommendations for the treatment of COVID-19 for patients in this group. this article describes a clinical case of persistent COVID-19 course in a comorbid patient with primary central nervous system large b-cell lymphoma during chemotherapy. © 2024 ABV-press Publishing House. All rights reserved.

Authors
Polyakov Yu.Yu. , Baryakh E.A. , Misyurina E.N. , Zhelnova E.I. , Mingalimov M.A. , Kardovskaya S.A. , Smolyarchuk M.Ya. , Tolstykh T.N. , Chudnova T.S. , Ivanova D.D. , Kochneva O.L. , Lebedev D.V. , Abueva A.U. , Chistov A.M. , Zotina E.N. , Samsonova I.V. , Lysenko M.A.
Journal
Nervno-Myshechnye Bolezni
Publisher
ABV-Press Publishing House
Issue number
2
Language
Russian
Pages
101-108
State
Published
Link
External link
DOI
10.17650/1818-8346-2024-19-2-101-108
Volume
19
Year
2024
Organizations
  • 1 City Clinical Hospital No. 52, Moscow Healthcare Department, 3 Pekhotnaya St., Moscow, 123182, Russian Federation
  • 2 I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University), Build. 2, 8 Trubetskaya St., Moscow, 119991, Russian Federation
  • 3 Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia, Build. 1, 2/1 Barrikadnaya St., Moscow, 125993, Russian Federation
  • 4 Medicine and Nuclear Technologies LLC, Build. 322, 1 Akademika Kurchatova Ploshchad’, Moscow, 123098, Russian Federation
  • 5 Medical and Biological University of Innovation and Continuing Education, State Scientific Center of the Russian Federation, A.I. Burnazyan Federal Medical Biophysical Center, Federal Medical and Biological Agency, 46 Zhivopisnaya St., Russiа, Moscow, 123098, Russian Federation
  • 6 Peoples’ Friendship University of Russia named after Patrice Lumumba, 6 Miklukho-Maklaya St., Moscow, 117198, Russian Federation
  • 7 N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, 1 Ostrovityanova St., Moscow, 117997, Russian Federation
Keywords
chemotherapy; new coronavirus infection; primary central nervous system large b-cell lymphoma; virus persistence
Cite
ГОСТ MLA RIS BibTex
Share

Other records